Axeleos

Axeleos is a French biotechnology company dedicated to developing first-in-class monoclonal antibodies for the treatment of aggressive cancers. Spun out from the Cancer Research Center of Lyon (CRCL), the company focuses on the AXL receptor tyrosine kinase, a protein significantly involved in tumor resistance to conventional therapies and immune system evasion. Their lead therapeutic program aims to inhibit AXL signaling to reverse epithelial-to-mesenchymal transition and restore sensitivity to treatments in solid tumors. By addressing these fundamental mechanisms of cancer progression, Axeleos seeks to provide new hope for patients with hard-to-treat malignancies such as non-small cell lung cancer and pancreatic cancer. The company is backed by prominent investors including Kurma Partners and Bpifrance.